File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Mesenchymal Stem Cell Therapy for rheumatic diseases

TitleMesenchymal Stem Cell Therapy for rheumatic diseases
Authors
KeywordsMesenchymal Stem cells
Systemic lupus erythromatosis
Rheumatoid arthritis
Systemic sclerosis
Issue Date2016
PublisherDe Gruyter Open. The Journal's web site is located at http://www.rheumatology.org.hk/index/hong-kong-bulletin-on-rheumatic-diseases
Citation
Hong Kong Bulletin on Rheumatic Diseases, 2016, v. 16 n. 1, p. 6-10 How to Cite?
AbstractMesenchymal stem cell therapy (MSCT) is an innovative treatment for rheumatic diseases. Underlying mechanism of how MSCT works in rheumatic diseases are still uncertain and with various hypotheses. Animal studies in MSCT show conflicting results mainly attributed by the differences in administration methods of MSCT, types of MSC use and randomization procedures. Human studies of MSCT are so far small scale but with satisfactory results in patients with systemic lupus erythematosus (SLE). Human studies of MSCT, however, showed less rewarding results in patients with rheumatoid arthritis (RA) and systemic sclerosis (SSc). Larger scale studies are needed to confirm the efficiency of MSCT as well as the safety profile in human use.
Persistent Identifierhttp://hdl.handle.net/10722/238672
ISSN

 

DC FieldValueLanguage
dc.contributor.authorYeung, WWY-
dc.contributor.authorLau, CS-
dc.date.accessioned2017-02-20T01:24:35Z-
dc.date.available2017-02-20T01:24:35Z-
dc.date.issued2016-
dc.identifier.citationHong Kong Bulletin on Rheumatic Diseases, 2016, v. 16 n. 1, p. 6-10-
dc.identifier.issn2415-153X-
dc.identifier.urihttp://hdl.handle.net/10722/238672-
dc.description.abstractMesenchymal stem cell therapy (MSCT) is an innovative treatment for rheumatic diseases. Underlying mechanism of how MSCT works in rheumatic diseases are still uncertain and with various hypotheses. Animal studies in MSCT show conflicting results mainly attributed by the differences in administration methods of MSCT, types of MSC use and randomization procedures. Human studies of MSCT are so far small scale but with satisfactory results in patients with systemic lupus erythematosus (SLE). Human studies of MSCT, however, showed less rewarding results in patients with rheumatoid arthritis (RA) and systemic sclerosis (SSc). Larger scale studies are needed to confirm the efficiency of MSCT as well as the safety profile in human use.-
dc.languageeng-
dc.publisherDe Gruyter Open. The Journal's web site is located at http://www.rheumatology.org.hk/index/hong-kong-bulletin-on-rheumatic-diseases-
dc.relation.ispartofHong Kong Bulletin on Rheumatic Diseases-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectMesenchymal Stem cells-
dc.subjectSystemic lupus erythromatosis-
dc.subjectRheumatoid arthritis-
dc.subjectSystemic sclerosis-
dc.titleMesenchymal Stem Cell Therapy for rheumatic diseases-
dc.typeArticle-
dc.identifier.emailLau, CS: cslau@hku.hk-
dc.identifier.authorityLau, CS=rp01348-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1515/hkbrd-2016-0002-
dc.identifier.hkuros271135-
dc.identifier.volume16-
dc.identifier.issue1-
dc.identifier.spage6-
dc.identifier.epage10-
dc.publisher.placeGermany-
dc.identifier.issnl1680-4341-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats